Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States

被引:354
作者
El-Serag, HB
Mason, AC
Key, C
机构
[1] Houston VA Med Ctr, Gastroenterol Sect, Houston, TX 77211 USA
[2] Houston VA Med Ctr, Sect Hlth Serv Res, Houston, TX USA
[3] Baylor Coll Med, Houston, TX 77030 USA
[4] Albuquerque Vet Affairs Med Ctr, Albuquerque, NM USA
[5] Univ New Mexico, Albuquerque, NM 87131 USA
[6] Univ New Mexico Hosp, Albuquerque, NM USA
关键词
D O I
10.1053/jhep.2001.21041
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The recent increase in the incidence of hepatocellular cancer in the United States is thought to underlie the rising mortality of this malignancy. However, it remains unknown whether survival of patients with hepatocellular carcinoma (HCC) has changed during the same time period. Using the SEER database (Surveillance, Epidemiology, and End Results) of the National Cancer Institute, we examined the temporal changes and determinants of survival among patients with histologically proven HCC over a 20-year period. Between 1977 and 1996, 7,389 patients diagnosed with HCC were followed in the survival database of SEER, The overall 1-year relative survival rate increased from 14% (95% confidence intervals (CI): 12-16) during 1977-1981 to 23% (95% CI: 21-24) during 1992 to 1996. Between the same two time periods, less improvement was seen in the S-year survival rates, which increased from 2% (95% CI: 1-3) to only 5% (95% CI: 4-7), The median survival increased slightly from 0.57 years during 1977 to 1981 to 0.64 years during 1992 to 1996, In general, there were no significant differences in survival between men and women or between ethnic groups. During 1987 to 1991, a small fraction (0.8%) of patients underwent radical surgery; these patients had 1-year survival of 59% (95% CI: 35-83%), and 5-year survival of 35% (95% CI: 12-58%). Similar rates were seen during 1992-1996. In conclusion, a small improvement in survival of patients with HCC was seen between 1977 and 1996. Most of this apparent benefit is restricted to the first year following cancer diagnosis, raising the possibility of lead-time bias. There were no significant differences related to gender or ethnicity.
引用
收藏
页码:62 / 65
页数:4
相关论文
共 13 条
[1]
[Anonymous], INT CLASS DIS ONC
[2]
Bruix J, 1997, HEPATOLOGY, V25, P259
[3]
CHLEBOWSKI RT, 1984, CANCER-AM CANCER SOC, V53, P2701, DOI 10.1002/1097-0142(19840615)53:12<2701::AID-CNCR2820531224>3.0.CO
[4]
2-B
[5]
DIBISCEGLIE AM, 1999, SCHIFFS DIS LIVER, P1281
[6]
EDERER FRED, 1961, NATL CANCER INST MONOGR, V6, P101
[7]
Rising incidence of hepatocellular carcinoma in the United States [J].
El-Serag, HB ;
Mason, AC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (10) :745-750
[8]
Survival of patients with primary liver cancer, pancreatic cancer and biliary tract cancer in Europe [J].
Faivre, J ;
Forman, D ;
Estève, J ;
Obradovic, M ;
Sant, M .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (14) :2184-2190
[9]
Cancer statistics, 1998 [J].
Landis, SH ;
Murray, T ;
Bolden, S ;
Wingo, PA .
CA-A CANCER JOURNAL FOR CLINICIANS, 1998, 48 (01) :6-+
[10]
ODHE DC, 1974, AM J MED, V56, P83